Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98,143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report.
Zhao J, Li X, Fan R, Qin Y, Wang Z, Wang B, Li S, Fan J, Wu X, Liu H, Guan Y, Liang Y, Zhang X, Guo Y. Zhao J, et al. Among authors: li s, li x. Front Pharmacol. 2022 Nov 23;13:1060460. doi: 10.3389/fphar.2022.1060460. eCollection 2022. Front Pharmacol. 2022. PMID: 36506539 Free PMC article.
Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review.
Zhang X, Han H, Zhao J, Liu X, Zhang J, Sun R, Li S, Liu B, Zhu H, Jiao S, Li X, Tang H. Zhang X, et al. Among authors: li s, li x. Front Pharmacol. 2022 Aug 17;13:964606. doi: 10.3389/fphar.2022.964606. eCollection 2022. Front Pharmacol. 2022. PMID: 36059942 Free PMC article.
The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial.
Wang L, He Z, Yang S, Tang H, Wu Y, Li S, Han B, Li K, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Chen W, Luo Y, Wu L, Wang X, Nan K, Jin F, Dong J, Li B, Sun Y, Wang Q. Wang L, et al. Among authors: li s, li k, li b. Transl Lung Cancer Res. 2019 Oct;8(5):575-583. doi: 10.21037/tlcr.2019.09.21. Transl Lung Cancer Res. 2019. PMID: 31737494 Free PMC article.
[No title available]
Li|Sheng||S [No authors listed] PMID: 39562650
98,143 results
You have reached the last available page of results. Please see the User Guide for more information.